Invention Application
- Patent Title: CHIMPANZEE ADENOVIRAL VECTOR-BASED FILOVIRUS VACCINES
-
Application No.: US16751470Application Date: 2020-01-24
-
Publication No.: US20200149069A1Publication Date: 2020-05-14
- Inventor: Nancy J. Sullivan , Gary J. Nabel , Clement Asiedu , Cheng Cheng , Alfredo Nicosia , Riccardo Cortese , Virginia Ammendola , Stefano Colloca
- Applicant: The Government of the United States of America as Represented by the Secretary of the Department of , GlaxoSmithKline Biologicals SA
- Applicant Address: US MD Rockville BE Rixensart
- Assignee: The Government of the United States of America as Represented by the Secretary of the Department of,GlaxoSmithKline Biologicals SA
- Current Assignee: The Government of the United States of America as Represented by the Secretary of the Department of,GlaxoSmithKline Biologicals SA
- Current Assignee Address: US MD Rockville BE Rixensart
- Main IPC: C12N15/86
- IPC: C12N15/86 ; C12N7/00 ; C07K14/005 ; A61K39/12
Abstract:
This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
Information query
IPC分类:
